MeiraGTx Holdings PLC $MGTX Shares Purchased by Privium Fund Management B.V.

Privium Fund Management B.V. grew its stake in shares of MeiraGTx Holdings PLC (NASDAQ:MGTX) by 39.3% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 163,000 shares of the company’s stock after purchasing an additional 46,000 shares during the quarter. Privium Fund Management B.V. owned approximately 0.20% of MeiraGTx worth $1,056,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of MGTX. Adage Capital Partners GP L.L.C. grew its position in shares of MeiraGTx by 11.9% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 5,634,578 shares of the company’s stock valued at $38,202,000 after buying an additional 600,000 shares during the last quarter. Invesco Ltd. boosted its stake in MeiraGTx by 1,628.7% in the first quarter. Invesco Ltd. now owns 350,401 shares of the company’s stock valued at $2,376,000 after acquiring an additional 330,131 shares in the last quarter. 683 Capital Management LLC boosted its stake in MeiraGTx by 6.6% in the first quarter. 683 Capital Management LLC now owns 2,575,000 shares of the company’s stock valued at $17,458,000 after acquiring an additional 160,000 shares in the last quarter. Affinity Asset Advisors LLC acquired a new stake in shares of MeiraGTx during the first quarter worth about $1,017,000. Finally, Nuveen LLC acquired a new stake in shares of MeiraGTx during the first quarter worth about $1,012,000. Hedge funds and other institutional investors own 67.48% of the company’s stock.

MeiraGTx Stock Up 6.3%

MGTX opened at $8.24 on Tuesday. MeiraGTx Holdings PLC has a 52 week low of $4.55 and a 52 week high of $8.98. The business has a 50 day moving average price of $7.88 and a two-hundred day moving average price of $7.03. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 26.29. The company has a market cap of $662.91 million, a PE ratio of -4.04 and a beta of 1.34.

MeiraGTx (NASDAQ:MGTX) last released its earnings results on Thursday, August 14th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.04. MeiraGTx had a negative return on equity of 314.44% and a negative net margin of 415.39%.The business had revenue of $3.69 million for the quarter, compared to analyst estimates of $8.00 million. As a group, research analysts anticipate that MeiraGTx Holdings PLC will post -1.48 EPS for the current year.

Insider Buying and Selling at MeiraGTx

In other news, CEO Alexandria Forbes sold 47,500 shares of the business’s stock in a transaction dated Tuesday, October 7th. The shares were sold at an average price of $8.39, for a total transaction of $398,525.00. Following the transaction, the chief executive officer directly owned 1,313,983 shares in the company, valued at $11,024,317.37. The trade was a 3.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 7.50% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on MGTX. Chardan Capital reissued a “buy” rating and issued a $35.00 target price on shares of MeiraGTx in a research report on Friday, August 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of MeiraGTx in a report on Wednesday, October 8th. Finally, Wall Street Zen raised shares of MeiraGTx from a “sell” rating to a “hold” rating in a report on Saturday, July 5th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, MeiraGTx currently has an average rating of “Hold” and an average target price of $24.00.

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.